HomeCompareCAH vs ALGN

CAH vs ALGN: Dividend Comparison 2026

CAH yields 0.99% · ALGN yields 1.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAH wins by $159.00 in total portfolio value· pulled ahead in Year 7
10 years
CAH
CAH
● Live price
0.99%
Share price
$206.31
Annual div
$2.04
5Y div CAGR
5.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$185.04
Full CAH calculator →
ALGN
ALGN
● Live price
1.20%
Share price
$166.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$130.06
Full ALGN calculator →

Portfolio growth — CAH vs ALGN

📍 CAH pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAHALGN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAH + ALGN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAH pays
ALGN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAH
Annual income on $10K today (after 15% tax)
$83.95/yr
After 10yr DRIP, annual income (after tax)
$157.28/yr
ALGN
Annual income on $10K today (after 15% tax)
$102.25/yr
After 10yr DRIP, annual income (after tax)
$110.55/yr
At 15% tax rate, CAH beats the other by $46.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAH + ALGN for your $10,000?

CAH: 50%ALGN: 50%
100% ALGN50/50100% CAH
Portfolio after 10yr
$21.5K
Annual income
$157.55/yr
Blended yield
0.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALGN right now

CAH
Analyst Ratings
18
Buy
15
Hold
Consensus: Buy
Price Target
$252.33
+22.3% upside vs current
Range: $220.00 — $275.00
Altman Z
4.8
Piotroski
5/9
ALGN
Analyst Ratings
24
Buy
7
Hold
2
Sell
Consensus: Buy
Price Target
$197.30
+18.7% upside vs current
Range: $140.00 — $220.00
Altman Z
4.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAH buys
0
ALGN buys
0
No recent congressional trades found for CAH or ALGN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAHALGN
Forward yield0.99%1.20%
Annual dividend / share$2.04$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.6%0%
Portfolio after 10y$21.6K$21.4K
Annual income after 10y$185.04$130.06
Total dividends collected$1.4K$1.3K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$252.33$197.30

Year-by-year: CAH vs ALGN ($10,000, DRIP)

YearCAH PortfolioCAH Income/yrALGN PortfolioALGN Income/yrGap
1$10,804$104.30$10,820$120.29$16.00ALGN
2$11,672$111.21$11,699$121.65$27.00ALGN
3$12,607$118.57$12,641$122.92$34.00ALGN
4$13,616$126.40$13,650$124.13$34.00ALGN
5$14,704$134.73$14,731$125.27$27.00ALGN
6$15,877$143.59$15,889$126.34$12.00ALGN
7← crossover$17,142$153.02$17,128$127.36+$14.00CAH
8$18,504$163.04$18,455$128.31+$49.00CAH
9$19,973$173.70$19,876$129.21+$97.00CAH
10$21,557$185.04$21,398$130.06+$159.00CAH

CAH vs ALGN: Complete Analysis 2026

CAHHealthcare

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Full CAH Calculator →

ALGNStock

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Full ALGN Calculator →
📬

Get this CAH vs ALGN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAH vs SCHDCAH vs JEPICAH vs OCAH vs KOCAH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.